Professor Jindong Chen is the company's Chief Technology Officer. He  is in charge of the research and development of new anti-metastasis drugs. Professor Chen earned his Ph.D. at the Karolinska Institute, in Sweden in 2000, and worked there as a postdoctoral fellow. He then become a Research Scientist at the Van Andel Research Institute. In 2011, he became a senior scientist at the National Cancer Institute Singapore and NUS-Duke University Graduate School. In 2012, Dr. Chen was appointed as an associate professor and Co-Director of the Renal Cancer Research Laboratory in the Department of Urology at the University of Rochester Medical Center (USA). Dr. Chen possesses 30 years of rich biomedical research experience with more than 100 publications, and is an expert in molecular biology and animal modeling experiments focusing on molecular mechanisms and anti-cancer drug screening for breast cancer, colorectal carcinoma, kidney tumors, and lung cancer. He has position-cloned a number of kidney cancer-related genes including NORE1, LSAMP, and HRPT2. He has also developed many conditional knockout mouse models including Flcn-Sglt2-Cre, Flcn-Ksp-Cre, Flcn-ER-Cre, Flcn-CMV-Cre, Vhl-Sglt2-Cre, Hrpt2-Ksp-Cre, Hrpt2-Sglt2-Cre, Hrpt2-CMV-Cre, Pbrm1-Ksp-Cre, Pbrm1-Sglt2-Cre, Pbrm1-CMV-Cre, Vhl-Flcn double knockout, and Vhl-Pbrm1 double knockout mouse models. For the above contributions, he was twice awarded prizes by the American Association of Cancer Research Meeting (AACR) (the 100th Sanofi-Aventis Scholar-in-Training Award in 2009, and the 94th AACR-Bristol-Myers Squibb Oncology Scholar-in Training Award in 2003, and was invited to participate a related press conference held by AACR). He has tested numerous anti-cancer drugs in his knockout and nude allograft/xenograft mouse models and obtained statistically meaningful results. In 2013, he edited the book Renal Tumor; and in 2016, he donated one of the knockout mouse models to The Jackson Laboratory (028718 - B6.129S4(SJL)-Flcntm1Btt/JdchJ). And in 2016, he edited another published book entitled Colorectal Cancer.
       As the Chief Technology Officer of Exploring Health LLC., Dr. Chen has led his team to develop several in vitro and in vivo anti-metastasis drug-screening platforms, a wound-healing drug-screening platform, and an anti-coronavirus drug-screening platform. To date, his team has five patents granted and three pending.